Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2022 | Developing programs focusing on lifestyle interventions to manage MS

Agne Straukiene • 16 Mar 2022
CONy 2022
Multiple Sclerosis and Related Disorders

Agne Straukiene, MD, Torbay and South Devon NHS Foundation Trust, Torquay, UK, describes the current state of programs and studies aiming to provide lifestyle changes in patients with multiple sclerosis (MS). Whilst multiple organizations have developed guidelines and apps to address lifestyle interventions across various countries, the sheer number of programs may confuse patients. Dr Straukiene emphasizes the need for personalized, location-based programs to improve outcomes in patients. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.

More from Agne Straukiene

Assessing the relevance of lifestyle interventions for managing MS
1:45
Assessing the relevance of lifestyle interventions for managing MS
Agne Straukiene • 16 Mar 2022
Elucidating the causes of MS with evidence-based studies
1:50
Elucidating the causes of MS with evidence-based studies
Agne Straukiene • 16 Mar 2022
Lifestyle interventions in MS management
2:58
Lifestyle interventions in MS management
Agne Straukiene • 16 Mar 2022

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals